655 related articles for article (PubMed ID: 29345000)
1. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
Begemann D; Anastos H; Kyprianou N
Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
[TBL] [Abstract][Full Text] [Related]
2. Profiling Prostate Cancer Therapeutic Resistance.
Wade CA; Kyprianou N
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
[TBL] [Abstract][Full Text] [Related]
3. Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.
El-Sayed IY; Daher A; Destouches D; Firlej V; Kostallari E; Maillé P; Huet E; Haidar-Ahmad N; Jenster G; de la Taille A; Abou Merhi R; Terry S; Vacherot F
Cancer Lett; 2017 Dec; 410():100-111. PubMed ID: 28935391
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
Nakazawa M; Kyprianou N
J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
[TBL] [Abstract][Full Text] [Related]
6. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
[TBL] [Abstract][Full Text] [Related]
7. Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.
Livas L; Hasani S; Kyprianou N
Adv Exp Med Biol; 2020; 1296():183-198. PubMed ID: 34185293
[TBL] [Abstract][Full Text] [Related]
8. The evolving role of immune cells in prostate cancer.
Wang C; Zhang Y; Gao WQ
Cancer Lett; 2022 Jan; 525():9-21. PubMed ID: 34715253
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
[TBL] [Abstract][Full Text] [Related]
10. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells.
Zhu ML; Kyprianou N
FASEB J; 2010 Mar; 24(3):769-77. PubMed ID: 19901020
[TBL] [Abstract][Full Text] [Related]
11. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
12. PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.
Pu H; Horbinski C; Hensley PJ; Matuszak EA; Atkinson T; Kyprianou N
Carcinogenesis; 2014 Nov; 35(11):2592-601. PubMed ID: 25173886
[TBL] [Abstract][Full Text] [Related]
13. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-mesenchymal transition in prostate cancer: an overview.
Montanari M; Rossetti S; Cavaliere C; D'Aniello C; Malzone MG; Vanacore D; Di Franco R; La Mantia E; Iovane G; Piscitelli R; Muscariello R; Berretta M; Perdonà S; Muto P; Botti G; Bianchi AAM; Veneziani BM; Facchini G
Oncotarget; 2017 May; 8(21):35376-35389. PubMed ID: 28430640
[TBL] [Abstract][Full Text] [Related]
15. Anoikis in phenotypic reprogramming of the prostate tumor microenvironment.
Nepali PR; Kyprianou N
Front Endocrinol (Lausanne); 2023; 14():1160267. PubMed ID: 37091854
[TBL] [Abstract][Full Text] [Related]
16. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
Taplin ME
Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
[TBL] [Abstract][Full Text] [Related]
17. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
Altschuler J; Stockert JA; Kyprianou N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
[TBL] [Abstract][Full Text] [Related]
18. Nur77 suppression facilitates androgen deprivation-induced cell invasion of prostate cancer cells mediated by TGF-β signaling.
Wu J; Sun H; Yang X; Sun X
Clin Transl Oncol; 2018 Oct; 20(10):1302-1313. PubMed ID: 29594945
[TBL] [Abstract][Full Text] [Related]
19. Epithelial plasticity in prostate cancer: principles and clinical perspectives.
Das R; Gregory PA; Hollier BG; Tilley WD; Selth LA
Trends Mol Med; 2014 Nov; 20(11):643-51. PubMed ID: 25262538
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cell and mesenchymal cell cooperative actions in metastasis progression and hormone resistance in prostate cancer: Potential role of androgen and gonadotropin‑releasing hormone receptors (Review).
Contreras HR; López-Moncada F; Castellón EA
Int J Oncol; 2020 May; 56(5):1075-1082. PubMed ID: 32319606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]